{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:03Z","timestamp":1790717103920,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Swiss Cancer League","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neo.2021.07.001","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T05:02:19Z","timestamp":1627362139000},"page":"929-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL\/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors"],"prefix":"10.1016","volume":"23","author":[{"given":"Gabriele","family":"Manzella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devmini C.","family":"Moonamale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"R\u00f6mmele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat W.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2021.07.001_bib0001","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2021.07.001_bib0002","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pbc.24435","article-title":"Children's oncology group's 2013 blueprint for research: soft tissue sarcomas","volume":"60","author":"Hawkins","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.neo.2021.07.001_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0142(19830701)52:1<44::AID-CNCR2820520110>3.0.CO;2-V","article-title":"Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I","volume":"52","author":"Raney","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2021.07.001_bib0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1995.13.3.610","article-title":"The third intergroup rhabdomyosarcoma study","volume":"13","author":"Crist","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2021.07.001_bib0005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djt007","article-title":"The clinical relevance of cancer cell lines","volume":"105","author":"Gillet","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.neo.2021.07.001_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neo.2021.07.001_bib0007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.neo.2021.07.001_bib0008","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.neo.2021.07.001_bib0009","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1038\/s41467-020-18388-7","article-title":"Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity","volume":"11","author":"Manzella","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neo.2021.07.001_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2021.07.001_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2021.07.001_bib0012","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.neo.2021.07.001_bib0013","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/onc.2015.440","article-title":"Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma","volume":"35","author":"Heinicke","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2021.07.001_bib0014","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.18632\/oncotarget.2726","article-title":"Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma","volume":"6","author":"Graab","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2021.07.001_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.canlet.2016.07.007","article-title":"Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs","volume":"381","author":"Meister","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.neo.2021.07.001_bib0016","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-11-0759","article-title":"2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma","volume":"71","author":"Ramirez-Peinado","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2021.07.001_bib0017","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2021.07.001_bib0018","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/sj.onc.1203607","article-title":"Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3\/FKHR","volume":"19","author":"Margue","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2021.07.001_bib0019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2017.09.025","article-title":"BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis","volume":"412","author":"Faqar-Uz-Zaman","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.neo.2021.07.001_bib0020","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1038\/s41467-018-05815-z","article-title":"Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity","volume":"9","author":"Soderquist","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.neo.2021.07.001_bib0021","series-title":"Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis","author":"Kehr","year":"2020"},{"key":"10.1016\/j.neo.2021.07.001_bib0022","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.neo.2021.07.001_bib0023","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2021.07.001_bib0024","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 Is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.neo.2021.07.001_bib0025","first-page":"61","article-title":"Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes","volume":"24","author":"Pazzaglia","year":"2009","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.neo.2021.07.001_bib0026","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1158\/1078-0432.CCR-03-0774","article-title":"Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide","volume":"10","author":"Thallinger","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2021.07.001_bib0027","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41419-020-02887-y","article-title":"Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance","volume":"11","author":"Alcon","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.neo.2021.07.001_bib0028","doi-asserted-by":"crossref","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","article-title":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer","volume":"112","author":"Faber","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2021.07.001_bib0029","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-19-1479","article-title":"Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with navitoclax to induce rhabdomyosarcoma cell death","volume":"80","author":"Ommer","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2021.07.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0348","article-title":"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation","volume":"8","author":"Anderson","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neo.2021.07.001_bib0031","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.neo.2021.07.001_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15384047.2015.1108485","article-title":"Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer","volume":"17","author":"Nakajima","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.neo.2021.07.001_bib0033","doi-asserted-by":"crossref","first-page":"35287","DOI":"10.1074\/jbc.M113.495986","article-title":"Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein","volume":"288","author":"Preuss","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2021.07.001_bib0034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.07.001_bib0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2021.07.001_bib0036","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2021.07.001_bib0037","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1172\/JCI85057","article-title":"Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma","volume":"126","author":"Bohm","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neo.2021.07.001_bib0038","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1158\/1535-7163.MCT-08-1147","article-title":"Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma","volume":"8","author":"Oesch","year":"2009","journal-title":"Mol Cancer Ther"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:09:31Z","timestamp":1761484171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1476558621000555"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.07.001","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL\/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}